Hypotheses on the Etiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Authors:
- Robert A.F. de Lind van WijngaardenRWRobert A.F. de Lind van Wijngaarden
- E. Christiaan HagenEHE. Christiaan Hagen
- Jan Willem Cohen TervaertJTJan Willem Cohen Tervaert
- Alfred D. MahrAMAlfred D. Mahr
Open Access
- 1 January 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 3 (1) , 237-252
Abstract
The first description of what is now known as antineutrophil cytoplasmic autoantibody–associated necrotizing vasculitis appeared more than 140 yr ago. Since then, many aspects of the pathogenic pathway have been elucidated, indicating the involvement of antineutrophil cytoplasmic autoantibodies, but why antineutrophil cytoplasmic autoantibodies are produced in the first place remains unknown. Over the years, many hypotheses have emerged addressing the etiology of antineutrophil cytoplasmic antibody production, but no exclusive factor or set of factors can so far be held responsible. Herein is reviewed the most influential hypotheses regarding the causes of antineutrophil cytoplasmic antibody–associated vasculitis with the aim of placing in an epidemiologic background the different hypotheses that are centered on environmental and genetic influences.Keywords
This publication has 191 references indexed in Scilit:
- Exposure to silica and risk of ANCA‐associated vasculitisAmerican Journal of Industrial Medicine, 2006
- New genomic region for Wegener?s granulomatosis as revealed by an extended association screen with 202 apoptosis-related genesHuman Genetics, 2004
- ANCA-associated diseases and silica exposureClinical Reviews in Allergy & Immunology, 1997
- Antineutrophil Cytoplasmic Autoantibodies Interact with Primary Granule Constituents on the Surface of Apoptotic Neutrophils in the Absence of Neutrophil PrimingJournal of Experimental Medicine, 1996
- T Cells Ignore the Parent Drug Propylthiouracil but Are Sensitized to a Reactive Metabolite Generatedin VivoClinical Immunology and Immunopathology, 1996
- Trimethoprim–Sulfamethoxazole (Co-Trimoxazole) for the Prevention of Relapses of Wegener's GranulomatosisNew England Journal of Medicine, 1996
- Anti—topoisomerase i antibodies in silica‐associated systemic sclerosis. A model for autoimmunityArthritis & Rheumatism, 1994
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994
- Wegener's Granulomatosis: Observations on Treatment With Antimicrobial AgentsMayo Clinic Proceedings, 1985
- Association of Wegener's granulomatosis with HLA-B8Clinical Immunology and Immunopathology, 1979